SIREN : 877822890
CHROMA BIOTECH is a French company founded 6 years ago, specialized in the sector Ennoblissement textile. Based in CAUDRY (59540), this company of category PME shows in 2024 a revenue of 2.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2 052 046 € | 2 383 021 € | 2 045 211 € | 1 441 832 € | 1 876 763 € |
| Net income | -1 875 € | -268 074 € | -362 607 € | 11 158 € | -66 138 € |
| EBITDA | -277 194 € | -71 246 € | -283 252 € | -422 911 € | -204 261 € |
| Net margin | -0.1% | -11.2% | -17.7% | 0.8% | -3.5% |
In 2024, CHROMA BIOTECH achieves revenue of 2.1 M€. Revenue is growing positively over 5 years (CAGR: +2.3%). Significant drop of -14% vs 2023. After deducting consumption (206 k€), gross margin stands at 1.8 M€, i.e. a rate of 90%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -277 k€, representing -13.5% of revenue. Warning negative scissor effect: despite revenue change (-14%), EBITDA varies by -289%, reducing margin by 10.5 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -2 k€ (-0.1% of revenue), which will impact equity.
2 052 046 €
1 845 839 €
-277 194 €
36 720 €
-1 875 €
-13.4%
The debt ratio (= Financial debt / Equity x 100) stands at 4192%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 2%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 9.8 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 7.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
4192.008%
1.883%
7.751%
9.778
56.6%
In 2024, the debt ratio of CHROMA BIOTECH (4192.01) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of CHROMA BIOTECH (1.9%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2024, the repayment capacity of CHROMA BIOTECH (9.78) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 140.65. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
140.654
-13.247
In 2024, the liquidity ratio of CHROMA BIOTECH (140.65) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of CHROMA BIOTECH (-13.2x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 31 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 48 days. Favorable situation: supplier credit is longer than customer credit by 17 days. Inventory turnover is 44 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 58 days of revenue, i.e. 329 k€ to permanently finance. Over 2020-2024, WCR increased by +173%, requiring additional financing.
329 148 €
31 j
48 j
44 j
58 j
Compare CHROMA BIOTECH with other companies in the same sector:
Voir toutes les statistiques du secteur Ennoblissement textile
The revenue of CHROMA BIOTECH in 2024 is 2.1 M€.
CHROMA BIOTECH recorded a net loss in 2024.
The headquarters of CHROMA BIOTECH is located in CAUDRY (59540), in the department Nord.
The tax return of CHROMA BIOTECH is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CHROMA BIOTECH operates in the sector Ennoblissement textile (NAF code 13.30Z). See the 'Sector positioning' section above to compare the company with its competitors.